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ORIGINAL AND CLINICAL ARTICLES
Diffuse alveolar haemorrhage (DAH) is a poten­
tially life­threatening condition defined as bleeding 
into alveolar space due to destruction of the pulmo­
nary capillaries. It can be associated with numerous 
disorders, but it most commonly develops in the 
course of systemic autoimmune diseases, such as 
antineutrophil cytoplasmic antibody (ANCA)­as­
sociated vasculitis (AAV) e.g., granulomatosis with 
polyangiitis (GPA) and microscopic polyangiitis 
(MPA), anti­glomerular basement membrane dis­
ease, and systemic lupus erythematosus (SLE) [1]. 
Diffuse alveolar haemorrhage is not a common con­
dition, occurring in 10–47% of patients with MPA, 
7–13% among patients with GPA and approxima­
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tely 5% of patients with systemic lupus erythema­
tosus [2­4]. 
It is hypothesized that the underlying mecha­
nisms are capillaritis and granular immune complex 
deposition in alveolar septae [4]. Diffuse alveolar 
haemorrhage can have a mild course with unspe­
cific symptoms such as fatigue, shortness of breath, 
through more alarming presentations, including 
haemoptysis and dyspnoea, up to severe respiratory 
failure requiring treatment in the intensive care unit 
(ICU). Moreover, the observed increase in incidence 
of autoimmune diseases [5, 6] might suggest that this 
syndrome will be more frequently seen in the ICU set­
ting. According to our knowledge, studies concern­
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Abstract
Background: Patients with autoimmune diseases constitute a relatively low percentage 
of the intensive care unit (ICU) population but their prognosis is particularly poor, par-
tially due to involvement of multiple organs as well as complications related to immu-
nosuppressive treatment. Diffuse alveolar haemorrhage (DAH) is one of the most life-
threatening presentations of autoimmune diseases, associated with worse outcomes. 
The aim of this study is to report about clinical factors associated with DAH in the ICU 
setting and to assess the survival in 5-year follow-up.
Methods: This is an observational, retrospective, cohort study performed in the ICU of 
the University Hospital in Krakow, Poland. We enrolled 21 patients treated for the first 
time in the ICU due to autoimmune diseases, who developed DAH. Severity of patients’ 
clinical condition was assessed on the first day using APACHE II, APACHE III, SAPS II 
and SOFA scores. Mortality was assessed during the ICU stay and in 5-year follow-up.
Results: The median age of the study population was 53 (18–78) years and 13 (61.9%) 
of patients were females. The most common diagnoses were granulomatosis with 
polyangiitis (38.1%), systemic lupus erythematosus (23.8%) and microscopic polyangi-
itis (14.3%). Most of the patients required mechanical ventilation (85.7%), renal replace-
ment therapy (57.1%) and blood product transfusions (71.4%). Mortality in the ICU was 
52.4%, while in both 1-year and 5-year follow-up it was 76.2%.
Conclusion: Patients who develop DAH in the course of autoimmune diseases and 
are treated in the ICU have a poor prognosis and often require advanced therapeutic 
measures.
Key words: autoimmune diseases, diffused alveolar haemorrhage, intensive care 
unit, mortality.
97
Diffuse alveolar haemorrhage in the ICU
ing patients with autoimmune diseases, treated in 
the ICU, who developed DAH, are very limited [7, 8]. 
Diagnosis of DAH is complex and poses a par­
ticular challenge in critically ill patients. The typical 
clinical symptom – hemoptysis – is present only in 
approximately one third of cases [1, 4]. The most cru­
cial imaging method is chest computed tomography 
(CT), which most often reveals ground glass opacities 
and/or alveolar consolidation with air bronchogram. 
Another important diagnostic method is a fibreop­
tic bronchoscopy with bronchoalveolar lavage (BAL) 
showing increasing haemorrhage in serial lavages 
and hemosiderin­laden macrophages found in the 
cytological examination. Basic laboratory tests usu­
ally show anaemia and, less specifically, increased 
lactate dehydrogenase (LDH) levels. One of the most 
typical features of DAH is increased diffusion lung 
capacity for carbon monoxide (DLCO) in lung func­
tion tests. The gold standard for the diagnosis of DAH 
is, however, surgical biopsy [4]. Obviously, in the ICU 
setting, some of the aforementioned methods pose 
too high a threat to patients. Therefore the diagnosis 
needs to be made on the basis of clinical examina­
tion, imaging and laboratory tests and bronchoscopy.
Our group has recently reported on the high 
mortality rate of ICU patients with systemic autoim­
mune diseases reaching up to 70% in 5­year follow­
up [9]. Considering that DAH is one of the most 
severe autoimmune disease manifestations, due 
to its sudden onset and potentially fatal outcome, 
prompt diagnosis and treatment are crucial [10]. Re­
ported mortality of DAH in the available literature 
is high but variable, ranging from 20% to 80% [11]. 
Previous reports suggest that shock, impaired renal 
function, as well as plasmatic lactate dehydroge­
nase levels are factors associated with in­hospital 
mortality in this population [12].
The aim of this study is to describe patients with 
DAH in the course of systemic autoimmune disease 
treated in the ICU with survival analysis in a 5­year 
follow­up.
METHODS
This is an observational, retrospective cohort 
study, conducted in the ICU of the Allergy and Im­
munology Department at the University Hospital in 
Krakow, Poland. The study is a part of the ICU pa­
tient database project, which was approved by the 
Jagiellonian University Bioethics Committee. Due to 
the nature of the study there was no requirement 
for written informed consent.
The study personnel searched the hospital’s 
electronic database from years 2001–2014 in order 
to identify patients with the diagnosis of systemic 
autoimmune diseases treated in the ICU. The 10th re­
vision of the International Statistical Classification 
of Diseases and Related Health Problems (ICD­10) 
codes as well as the full names of the systemic auto­
immune diseases were used in database screening. 
Each medical record was later thoroughly assessed 
to confirm patients’ eligibility for the study. Among 
patients included in the study, those diagnosed 
with DAH were selected for the analysis. The study 
flowchart is provided in Figure 1.
If the patient was treated in the ICU more than 
once, only the first admission was analyzed. Patients 
admitted to the ICU only for a single procedure 
(e.g. dialysis catheter implantation or therapeutic 
plasma exchange) were excluded from the study. 
Diagnosis of DAH was made by experienced clini­
cians according to commonly used criteria including 
clinical examination, laboratory tests, CT as well as 
bronchoscopy.
The study personnel gathered demographic, 
clinical and laboratory data. The reason for the ICU 
admission, history of autoimmune diseases and im­
munosuppressive treatment, procedures performed 
in the ICU and all variables concerning ICU stay were 
also extracted.
Based on available data from the first 24 hours 
of ICU stay, the authors calculated the following in­
dices: Acute Physiology and Chronic Health Evalua­
tion (APACHE) II and III, Simplified Acute Physiology 
Score (SAPS) II as well as the Sequential Organ Fail­
ure Assessment (SOFA) [13]. Patients’ survival was 
assessed at the ICU discharge, 1 year and 5 years 
after the first ICU admission by phone call follow­
up and other available resources (Outpatient Clinic 
Database, National Health Insurance Database).
Records assessment 
FIGURE 1. The study flowchart
ICU’s electronic 
database searched 
for terms: „systemic 
lupus erythematosus”, 
„vasculitis”, 
„granulomatosis with 
polyangiitis”, „Wegener’s 
granulomatosis”, 
„eosinophilic 
granulomatosis with 
polyangiitis”, „Churg-
Strauss syndrome”, 
„rheumatoid arthritis”, 
„polymyositis”, 
„dermatomyositis”, 
„scleroderma”, 
„systemic sclerosis”, 
„antiphospholipid 
syndrome”, „connective 
tissue disease”
Patients with diagnosis 
of systemic autoimmune 
disease, treated in the 
Intensive Care Unit 
n = 83 
9 patients excluded:
–  6 patients were 
previously hospitali-
zed in the ICU due to 
autoimmune disease
–  3 patients were admit-
ted to ICU for a single 
procedure 
n = 74 
53 patients excluded due 
to lack of DAH diagnosis 
during ICU hospitalization
n = 21 
ICU’s electronic databa-
se searched for ICD-10 
codes: M05, M06, M30, 
M31, M32, M33, M34, 
M35, M36, D68.9, D69
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Variables are described as mean with standard 
deviation (SD) or median with interquartile ranges 
depending on the data distribution. Comparisons 
between groups were performed using the c2 test 
for categorical variables, whereas continuous vari­
ables were compared using Student’s t test and the 
Mann Whitney U­test, depending on data distri­
bution. Survival was defined as the time from the 
ICU admission to death from any cause and event­
time distribution was graphically presented using 
Kaplan­Meier curves. Differences in mortality be­
tween the two study groups were assessed using 
the log­rank test. Statistical analysis was performed 
with StatSoft Statistica 13 software (StatSoft, Tulsa, 
OK, USA) and RStudio version 1.1.383 (RStudio, Bos­
ton, MA, USA); packages: survival, survminer. Graphs 
were prepared with GraphPad Prism 8 (GraphPad 
Software, San Diego, CA, USA) and RStudio version 
1.1.383 (RStudio, Boston, MA, USA); packages: sur­
vival, survminer.
RESULTS
Baseline demographic clinical 
characteristics
Of 74 patients with systemic autoimmune dis­
eases treated in the ICU between 2002 and 2014, we 
selected 21 who developed DAH. The median age of 
patients was 53 (range: 18–78) years and 13 (61.9%) 
of them were female. The majority of the patients 
were diagnosed with granulomatosis with polyan­
giitis (8/21; 38.1%), systemic lupus erythematosus 
(5/21; 23.8%) and microscopic polyangiitis (3/21; 
14.3%). The autoimmune disease was diagnosed 
during the ICU hospitalization in 4 cases (19.0%). 
Diffuse alveolar haemorrhage was the reason for 
admission in 6 patients (28.6%) and developed dur­
ing ICU hospitalization in 15 cases (71.4%). The most 
common comorbidity in this cohort was chronic 
kidney disease, which was diagnosed in 12 patients 
(57.1%), 7 (33.3%) of whom had end­stage chronic 
kidney disease. Detailed information concerning 
basic characteristics of the study group and auto­
immune disease diagnosis can be found in Table 1.
Pre-ICU immunosuppressive therapy
The majority of the patients (17/21; 81.0%) were 
administered at least one immunosuppressive med­
ication prior to admission to the ICU. Nine patients 
(42.9%) received long­term steroid therapy, twelve 
patients (57.1%) cyclophosphamide and in seven 
patients (33.3%) a combination of these medica­
tions was used.
ICU hospitalization
The most commonly used causal treatment was 
steroids in maintenance doses only (14/21, 66.7%), 
steroid pulses (6/21, 28.6%), cyclophosphamide 
infusions (6/21, 28.6%) and plasmapheresis (4/21, 
19.0%). The majority of the patients required me­
chanical ventilation (18/21, 85.7%), renal replace­
ment therapy (12/21, 57.1%) and blood product 
transfusions (15/21, 71.4%). A detailed description 
of the ICU management is summarized in Table 2. 
Survival analysis
Almost half of the patients survived the ICU 
hospitalization (10/21; 47.6%). The survival rate was 
23.8% (5/21) in both 1­year and 5­year follow­up. 
Five of the total eleven deaths during ICU stay were 
related to infection (45.5%). A detailed description 
TABLE 1. Basic demographic and clinical characteristics of the study group
Factor
Demographics
Females 13 (61.9%)
Age (years) 53 (18–78)
Primary diagnosis
Granulomatosis with polyangiitis 8 (38.1%)
Systemic lupus erythematosus 5 (23.8%)
Microscopic polyangiitis 3 (14.3%)
Polymyositis and dermatomyositis 2 (9.5%)
Rheumatoid arthritis 1 (4.8%)
Goodpasteur’s syndrome 1 (4.8%)
Scleroderma 1 (4.8%)
Comorbidities
Chronic kidney disease 12 (57.1%)
Hypertension 7 (33.3%)
Diabetes mellitus 5 (23.8%)
Pre-ICU treatment
Long-term steroids (> 3 months) 9 (42.9%)
Cyclophosphamide 12 (57.1%)
Steroids + cyclophosphamide 7 (33.3%)
Categorical variables are presented as number (%). Continuous variables are presented as median (range).
TABLE 2. Management in the intensive care unit (ICU)
ICU management
Diagnosis of autoimmune disease in the ICU 4 (19.0%)
ICU stay duration (days) 11 (2–21)
Steroid pulses 6 (28.6%)
Steroids 14 (66.7%)
Cyclophosphamide 6 (28.6%)
Plasmapheresis 4 (19.0%)
Mechanical ventilation 18 (85.7%)
Number of days on mechanical ventilation 6 (1–15)
Renal replacement therapy 12 (57.1%)
Blood products transfusion 15 (71.4%)
Categorical variables are presented as number (%). Continuous variables are presented as median (interquartile range).
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esis [8, 15] as well as recombinant activated factor 
VII (rFVIIa) [16]. There are also case report series of 
extracorporeal membrane oxygenation (ECMO) 
use in severe, hypoxic respiratory failure due to 
of the survival and the calculated SAPS II, APACHE II, 
APACHE III and 1st day SOFA scores can be found in 
Table 3. The Kaplan­Meier curve for 1­year survival 
is presented in Figure 2.
Comparison of study groups
Patients who developed DAH were less often 
administered steroids before admission to the ICU 
(42.9% vs. 69.8%, P = 0.03), were more often diag­
nosed with autoimmune disease in the ICU (19.0% 
vs. 3.8%, P = 0.03) and achieved a higher SAPS II score 
(55.0 vs. 41.0, P = 0.014). In terms of treatment dur­
ing ICU hospitalization, patients with DAH more of­
ten received steroid pulses (28.6% vs. 9.4%, P = 0.04), 
cyclophosphamide (28.6% vs. 5.7%, P = 0.007) and 
renal replacement therapy (57.1% vs. 28.3%, P = 0.02) 
compared to those who did not develop DAH. We did 
not observe any significant differences in survival 
between the groups. Exact data are presented in 
Tables 4 and 5. The Kaplan­Meier curve comparing 
survival in the two groups is shown in Figure 3.
DISCUSSION
In this retrospective cohort study, we analysed 
21 patients with systemic autoimmune diseases 
complicated by diffuse alveolar haemorrhage, treat­
ed in the intensive care unit. It showed that this con­
dition is associated with high short­term and long­
term mortality as well as significant requirement for 
advanced life­support procedures. This is, to our best 
knowledge, the first study describing characteristics 
and outcomes of Polish patients with systemic auto­
immune diseases, treated in the intensive care unit, 
who developed DAH. It also provides a unique in­
sight into long­term outcomes of this very specific 
group of patients. 
Our study confirms that among patients with 
systemic autoimmune diseases, DAH occurs most 
commonly among patients with ANCA­associated 
vasculitis. Interestingly, in almost 20% of patients 
in the study, autoimmune diseases were diagnosed 
during ICU hospitalization. Similar findings were ob­
tained in the study by Monti et al., where 30% of ICU­
diagnosed vasculitis patients had DAH [14]. It high­
lights the fact that this life­threatening complication 
is a hallmark presentation of autoimmune disease in 
a significant number of patients. In our opinion, these 
results suggest that there is still room for improve­
ment in early detection of autoimmune diseases 
before the most severe presentations, such as DAH, 
occur and higher vigilance of clinicians is warranted.
Typically, causal treatment of DAH consists of 
pulse corticosteroids and other intravenous immuno­
suppressants such as cyclophosphamide [11]. Other 
reports suggest the use of a monoclonal chimeric an­
tibody targeting CD20 (rituximab) [4], plasmapher­
Su
rv
iva
l p
ro
ba
bi
lit
y
St
ud
y g
ro
up
1.00
0.75
0.50
0.25
0
0 50 100 150 200 250 300 350
Time
0 50 100 150 200 250 300 350
21 9 8 7 6 5 5 5
53 26 25 24 23 23 23 23
P = 0.11
Time
Number at risk
FIGURE 3. The Kaplan-Meier curves comparing 1-year survival between patients 
with diffuse alveolar haemorrhage (DAH) (blue line) and those who did not develop 
DAH (red line)
No DAH DAH
TABLE 3. Prognostic scale scores and survival in the ICU as well as 1-year and 5-year 
follow-up
Prognostic scales
SAPS II 55 (22–99)
APACHE II 25 (10–48)
APACHE III 82 (43–167)
SOFA on 1st day 8 (2–19)
Survival
ICU 10 (47.6%)
1 year 5 (23.8%)
5 years 5 (23.8%)*
Categorical variables are presented as number (%). Continuous variables are presented as median (interquartile range).
*None of the patients died between 1-year and 5-year follow-up
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FIGURE 2. The Kaplan-Meier curve for 1-year survival among patients who developed 
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DAH [17, 18]. In our cohort the majority of patients 
were treated with steroids, more than 1 in 4 patients 
required steroid pulses or cyclophosphamide infu­
sions, in less than 20% of cases plasmaphereses 
were performed, while none of the patients re­
ceived rituximab. Due to the lack of well­designed 
studies and low prevalence of the described syn­
drome, there is lack of evidence­based guidelines 
concerning treatment of DAH in autoimmune dis­
eases. Hopefully, upcoming publication of PEXIVAS 
study results [19] will shed more light on the use­
fulness of plasmapheresis in treatment of DAH, es­
pecially considering that this topic is controversial, 
as there is not enough evidence of the treatment 
benefits, and the plasmapheresis procedure may 
also be associated with some complications [15]. 
It is important to remember that the key to DAH 
management is the successful treatment of under­
lying disease [10].
Another interesting observation is high use of 
advanced therapeutic procedures – the majority of 
our patients required mechanical ventilation, blood 
product transfusions and renal replacement thera­
py. Available literature mentions mainly invasive 
mechanical ventilation use, which is very variable 
and ranges from 17% to 70%. However, most of the 
studies concern patients treated outside the ICU 
[7, 12, 20]. Such frequent use of renal replacement 
therapy is probably associated with common renal 
involvement in autoimmune diseases, while blood 
product transfusions are related to blood loss result­
ing from haemorrhage.
Patients enrolled in our study were in a severe 
clinical condition from the moment of admission, 
which is reflected in high scores in all prognostic 
scales. As an example, the median score in SAPS II 
corresponds with predicted mortality of 57%. Our 
study showed that more than 50% of patients with 
systemic autoimmune diseases who developed 
DAH do not survive ICU hospitalization. In longer 
follow­up, there is a significant drop in survival to 
less than 25% at 1 year. Interestingly, none of the 
patients died within the following 4 years of obser­
vation. This finding has emphasized how important 
for patients’ prognosis is the ICU treatment and then 
check­ups during the following year. Compared to 
previous studies, the mortality in our cohort is mark­
edly higher. This is probably associated with the fact 
that our group consists exclusively of patients treat­
ed in the ICU. When compared to the study by Rabe 
et al., where DAH was assessed in the ICU setting 
(but not only in autoimmune diseases), the mortal­
ity rate is similar [7]. 
Additional analysis involving comparison of 
study groups, suggests that, even among patients 
with systemic autoimmune diseases, those who de­
velop DAH are admitted to the ICU in worse clinical 
condition, receive more intensive immunosuppres­
sive therapy and more often require renal replace­
TABLE 5. Comparison of study groups in terms of intensive care unit (ICU) management, 
prognostic scales scores and survival
Feature DAH
(n = 21)
No DAH 
(n = 53)
P-value
ICU management
Diagnosis of autoimmune 
disease in the ICU
4 (19.0%) 2 (3.8%) 0.03
ICU stay duration (days) 11 (2–21) 8 (5–17) 0.88
Steroid pulses 6 (28.6%) 5 (9.4%) 0.04
Steroids 14 (66.7%) 39 (73.6%) 0.55
Cyclophosphamide 6 (28.6%) 3 (5.7%) 0.007
Plasmapheresis 4 (19.0%) 3 (5.7%) 0.08
Mechanical ventilation 18 (85.7%) 35 (66.0%) 0.09
Number of days on mechanical 
ventilation
6 (1–15) 6 (0–10) 0.45
Renal replacement therapy 12 (57.1%) 15 (28.3%) 0.02
Blood products transfusion 15 (71.4%) 28 (52.8%) 0.14
Prognostic scales
SAPS II 55 (22–99) 41 (27.5–58) 0.014
APACHE II 25 (10–48) 22.5 (16–29) 0.33
APACHE III 82 (43–167) 76.5 (55–106.5) 0.24
SOFA on 1st day 8 (2–19) 7.5 (4–11) 0.23
Survival
ICU 10 (47.6%) 32 (60.4%) 0.32
1 year 5 (23.8%) 23 (43.4%) 0.11
5 years 5 (23.8%)* 14 (26.4%) 0.29
Categorical variables are presented as number (%). Continuous variables are presented as median (interquartile range).
*None of the patients died between 1-year and 5-year follow-up. 
DAH – diffuse alveolar haemorrhage
TABLE 4. Comparison of study groups in terms of demographics, comorbidities and 
immunosuppressive treatment before intensive care unit (ICU) admission
Feature DAH 
(n = 21)
No DAH
 (n = 53)
P-value
Demographics
Females 13 (61.9%) 40 (75.5%) 0.24
Age (years); median (range) 53 (18–78) 54 (20–81) 0.9
Comorbidities
Chronic kidney disease 12 (57.1%) 22 (41.5%) 0.22
Hypertension 7 (33.3%) 19 (35.8%) 0.84
Diabetes mellitus 5 (23.8%) 9 (17.0%) 0.5
Pre-ICU treatment
Long-term steroids (> 3 months) 9 (42.9%) 37 (69.8%) 0.03
Other immunosuppressants 12 (57.1%) 36 (67.9%) 0.77
Steroids + other immunosuppressants 7 (33.3%) 28 (52.8%) 0.13
Categorical variables are presented as number (%). Continuous variables are presented as median (interquartile range). 
DAH – diffuse alveolar haemorrhage
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ment therapy. Interestingly, there is no statistically 
significant difference in terms of survival between 
the groups. However, this is probably related to the 
limited sample size as 1­year survival in the DAH 
group is almost two times lower compared to the 
remaining patients.
Our study has several limitations. First, the study 
group is small, which limits our ability to perform 
multivariable analysis to assess e.g. mortality risk 
factors. Moreover, the retrospective character of 
the study hinders precise assessment of several 
crucial features, e.g. cause of death. Also, follow­up 
analysis concerned only mortality, and we had no 
information concerning DAH relapses and rehospi­
talizations.
CONCLUSIONS
Patients who develop DAH in the course of 
systemic autoimmune disease and require hospi­
talization in the ICU are at particularly high risk for 
mortality, and most of them require mechanical 
ventilation, renal replacement therapy and blood 
product transfusions.
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